Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference
19 févr. 2021 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology
16 févr. 2021 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH
19 janv. 2021 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH
05 janv. 2021 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Reports Positive Results from Phase 1 Trial of MET642
17 déc. 2020 06h30 HE
|
Metacrine, Inc.
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in...
Metacrine to Participate in Upcoming Investor Conferences
23 nov. 2020 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Reports Business Updates and Third Quarter 2020 Financial Results
12 nov. 2020 06h30 HE
|
Metacrine, Inc.
Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH $85 Million Initial Public Offering Completed SAN DIEGO, Nov. 12, 2020 (GLOBE...
Metacrine to Present New Data from MET409 Program in NASH at AASLD’s The Liver Meeting Digital Experience™
01 oct. 2020 16h01 HE
|
Metacrine, Inc.
SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Announces Pricing of Initial Public Offering
15 sept. 2020 21h52 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Strengthens Leadership Team with Key Appointments
02 sept. 2020 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver...